Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

BeOne Care Foundation

- PMLiVE

BeOne Medicines, BeOne Care Foundation and The Max Foundation renew partnership

This is to expand access to leukaemia treatment in low- and middle-income countries

- PMLiVE

NICE recommends treatments for mantle cell lymphoma and chronic lymphocytic leukaemia

The treatments are for eligible adults in England and Wales

- PMLiVE

BeOne Medicines appoints Kandeepan Ganeshalingam as Vice-President, Head of Medical Affairs, Europe

Ganeshalingam previously held senior leadership roles at Pfizer, Seagen, MSD and Roche

- PMLiVE

Eli Lilly shares positive results for Jaypirca in head-to-head CLL/SLL study

Around 23,690 cases of chronic lymphocytic leukaemia are expected to be diagnosed in the US this year

- PMLiVE

CHMP recommends BeOne Medicines’ Tevimbra for new lung cancer indication

Non-small cell lung cancer accounts for up to 90% of all lung cancer cases

- PMLiVE

NICE recommends BeOne’s Brukinsa to treat mantle cell lymphoma on NHS

Approximately 600 people are affected by the form of non-Hodgkin lymphoma every year in the UK

- PMLiVE

EC approves BeOne Medicines’ Tevimbra to treat nasopharyngeal cancer

The form of head and neck cancer accounted for around 133,000 new global cancer cases in 2020

- PMLiVE

CHMP recommends tablet formulation of BeOne’s targeted cancer drug Brukinsa

The new formulation would allow blood cancer patients to halve their daily pill intake

- PMLiVE

FDA approves tablet formulation of BeOne’s targeted cancer drug Brukinsa

The new formulation has been authorised for all five indications covered by the original capsule version

- PMLiVE

AstraZeneca’s Calquence approved by EC for first-line chronic lymphocytic leukaemia use

An estimated 27,000 cases of the disease were diagnosed in the UK, France, Germany, Spain and Italy in 2024

- PMLiVE

AstraZeneca’s Calquence combination shows promise in chronic lymphocytic leukaemia

Approximately 4,000 new cases of the disease are diagnosed in the UK every year

- PMLiVE

Janssen/Pharmacyclics’ ibrutinib shows continued survival benefit in chronic lymphocytic leukaemia

The slow-growing blood cancer affects approximately 4.92 per 100,000 people every year in Europe

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links